Estrogen receptor expression in luminal tumors & recurrence and metastasis

Sarah Anwar, MDLinx

San Antonio Breast Cancer Symposium 2017

San Antonio, Texas, United States | December 05-09, 2017

Luminal breast cancer subtypes are characterized by estrogen-receptor and estrogen-related genes, which sets them apart from other tumors that are not hormonally driven.

“Luminal B tumors have lower estrogen gene expression, and have higher expression of more proliferative types of genes,” says Angela DeMichele, MD, MSCE, professor of medicine and epidemiology, University of Pennsylvania.

So, whereas estrogen-receptor positive breast cancers don’t divide very quickly, “luminal B tumors are different. These tumors, while still having estrogen-related cell expression, are actually now dividing much more quickly due to the existence of these proliferative genes.”

In addition, estrogen-receptor positive breast tumors have “unique patterns of recurrence,” and reasons for this are not very well understood. It may be due to resistance, says Dr. DeMichele.

All Interviews

From this Conference

4:40

Implementing the TEAM approach to optimize concurrent palliative care
Oncologists should be open to implementing the TEAM approach to provide their patients the best concurrent palliative care possible, Thomas J. Smith, MD, FACP, FASCO, FAAHPM,...
Thomas J. Smith, MD, FACP, FASCO, FAAHPM
3:14

Managing patients with high risk breast lesions
Amy C. Degnim, MD, professor of surgery, Mayo Clinic, Rochester, MN, discusses the different management strategies for lesions that put patients at increased risk for breast...
Amy C. Degnim, MD
4:23

Circulating tumor cells as prognostic biomarkers for recurrence of breast cancer
At the 2018 Best of San Antonio Breast Cancer Symposium-New York, Joseph Sparano, MD, professor of medicine and women’s health, Albert Einstein College of Medicine,...
Joseph A. Sparano, MD

1:50

Conversion to response after failed immunotherapy
In some patients with cancer who have failed immune checkpoint blockade treatment, the addition of radiotherapy may bring about conversion to response.
Silvia Formenti, MD
0:52

Value of chemotherapy for patients with locoregional breast cancer recurrence
Although chemotherapy can positively impact patient outcomes after locoregional recurrence of breast cancer, this will generally occur only in patients with HR-negative (HR-)...
William Gradishar, MD
1:15

The paradoxical role of family history in breast cancer risk
Although family history can influence a patient’s risk of developing breast cancer, it does not increase that risk once other risk factors are identified.
Amy C. Degnim, MD

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium 2017.